ABIVAX Société Anonyme (ABVX)
| Market Cap | 8.90B +2,204.9% |
| Revenue (ttm) | 5.37M -63.2% |
| Net Income | -394.62M |
| EPS | -5.68 |
| Shares Out | 79.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 889,607 |
| Open | 113.00 |
| Previous Close | 113.00 |
| Day's Range | 110.60 - 115.57 |
| 52-Week Range | 5.59 - 148.83 |
| Beta | -0.10 |
| Analysts | Buy |
| Price Target | 131.31 (+14.62%) |
| Earnings Date | Mar 23, 2026 |
About ABVX
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Financial Performance
In 2025, ABIVAX Société Anonyme's revenue was 4.57 million, a decrease of -63.22% compared to the previous year's 12.43 million. Losses were -336.10 million, 90.7% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ABVX stock is "Buy." The 12-month stock price target is $131.31, which is an increase of 14.62% from the latest price.
News
Abivax to Present Data on Obefazimod at Digestive Disease Week®
Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical A...
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy?
Abivax's leading candidate looks very promising. However, between potential clinical setbacks and the biotech's high market cap, the stock looks risky.
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – Ap...
2 Healthcare Stocks That Could Soar Over the Next 5 Years
These two biotechs could ride the wave of significant clinical progress. However, both carry above-average risk.
Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
• Abivax stock is taking a hit today. Why is ABVX stock falling?
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC
Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter. Intense takeover rumors have surrounded the French bi...
2 Healthcare Stocks to Buy Before They Get Bought Out
Abivax is viewed as a buyout candidate thanks to its promising lead drug candidate, obefazimod. Abivax is testing obefazimod for multiple conditions.
Abivax spokesperson denies takeover rumors reported by French media
Biotechnology company Abivax dismissed information published by French media publication "La Lettre" saying it had granted AstraZeneca exclusive access to confidential information until March ...
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
British drugmaker AstraZeneca Plc (NYSE: AZN) has emerged as the leading contender to acquire French biotech Abivax SA (NASDAQ: ABVX), following the company's dramatic valuation surge after strong cli...
Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year
Abivax's shares have skyrocketed since David Cohen's fund first bought some shares. The company's leading candidate is promising, but there is substantial risk as well.
2 Reasons Abivax Stock Could 10X by 2036
Abivax's leading candidate could be a breakthrough treatment in ulcerative colitis. The medicine will likely target several other immunology conditions as well.
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly set the bar high, and it will be hard for other drugmakers to match its performance. Viking Therapeutics and Abivax are developing promising candidates.
Better Long-Term Buy: This Emerging Player or the Industry Leader?
AbbVie is a well-established drugmaker with fast-growing immunology products and a solid dividend program. Abivax could challenge pharmaceutical giants like AbbVie in a niche of the immunology market.
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid
Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may take over his company, and said market speculation about an ongoing revi...
Prediction: This Healthcare Stock Could Soar by 72% in 2026
Abivax has a potential transformative medicine in its pipeline that is attracting attention from other drugmakers. If the biotech gets acquired this year, its shares could soar.
France has had no request for investment approval in biotech Abivax - official
France's finance ministry has received no request seeking investment approval in Abivax and has had no contact with Eli Lilly , a ministry official said on Monday, following media reports that the U.S...
Abivax stock rockets 30% on Eli Lilly takeover speculation
Abivax stock (EPA: ABVX) surged roughly 30% in early Paris trading Monday after French media reported that US pharmaceutical giant Eli Lilly was preparing a €15 billion ($17.5 billion) acquisition off...
Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid
Stock in the French company has been rising steadily since late July, and climbed as much as 30% in early trading Monday.
Abivax shares soar 23% as media report reignites M&A chatter
Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine. Now, analysts say ...
Abivax Provides 2026 Corporate Outlook
Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader...
Why Abivax Stock Was on Fire Today
New speculation arose about a potential buyout from a very deep-pocketed strategic investor. These first started to swirl in mid-December.
Abivax to be Added to Nasdaq Biotechnology Index
Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinic...